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Background: Galectin-3 (Gal 3) is a novel marker of left heart failure and cardiovascular mortality. We tested the hypothesis that Gal-3 predicts 
pulmonary artery pressure and right ventricular (RV) function in pulmonary arterial hypertension (PAH).
methods: Using a prospective study, 15 subjects with right heart catheterization-proven PAH and 10 age-matched controls underwent same-day 
echocardiography, cardiac MRI (CMR), and phlebotomy for Gal 3 and creatinine. CMR was used to calculate left ventricular ejection fraction (LVEF), 
RV ejection fraction (RVEF), RV end systolic volume (RVESV), and RV mass. Echocardiography was used to estimate RV systolic pressure (RVSP) as 
well as assess RV diastolic function using tricuspid valve (TV) e’ velocity and E/e’.
Results: All PAH subjects were either idiopathic (N=12) or connective-tissue disease associated (N=3). There was no significant difference in age, 
gender, body mass index, estimated glomerular filtration rate, or LVEF between controls and PAH subjects. RVSP in PAH subjects was significantly 
elevated vs. controls (58 ± 17 mmHg vs. 26 ± 8 mmHg, p < .01). Gal-3 levels were significantly elevated in the PAH group when compared to 
controls (18 ± 5 vs. 11 ± 2, p < .01). Gal-3 levels positively correlated with RVSP (r 0.53, p < .01), RVESV (r .41, p < .04), RV mass (r 0.47, p < .01) 
and TV E/e’ (r .65, p < .01). Gal-3 negatively correlated with RVEF (r -0.41, p .04) and TV e’ (r -0.61, p < .01).
conclusion: This study suggests that Gal-3 levels may be predictive of pulmonary pressure, RV systolic function, diastolic function, and morphology 
independent of left ventricular systolic function and that Gal-3 may represent a novel biomarker for PAH diagnosis and monitoring. Larger studies 
would be necessary to confirm the findings from this small study.
